Apixaban
- PDF / 169,664 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 32 Downloads / 136 Views
1 S
Apixaban Oesophagitis: case report
A man in his 60s [age at onset of reaction not stated] developed oesophagitis during treatment with apixaban for non-valvular paroxysmal atrial fibrillation. The man had been receiving apixaban 5mg twice a day [route not stated] for non-valvular paroxysmal atrial fibrillation. He presented for the examination of epigastric pain and discomfort he had for approximately 1 year and were getting worse gradually. At that time, he did not have any other medications with possible gastrointestinal side effects. Subsequently, a gastrointestinal endoscopy was performed, which demonstrated longitudinal pinkish mucosal casts adhering to the middle and lower oesophagus. Additionally, reddish mucosal erosions were noted where the pinkish lesions had peeled off. Consequently, the man’s apixaban was stopped and changed to the unspecified direct anticoagulant. He continued lansoprazole therapy. He was recommended to drink enough water with medicine and stay seated for at least 30 minutes after taking any medicine to prevent drugs from adhering to the oesophageal mucosa. After 1 month at a follow-up, an esophagogastroduodenoscopy showed a remarkable improvement in the oesophageal mucosa. The disappearance of the pinkish mucosal casts and reddish mucosal erosion was noted. Therefore, it was considered that his oesophagitis was induced by apixaban. Kono Y, et al. A case of esophagitis induced by apixaban. Journal of Gastrointestinal and Liver Diseases 29: 471, No. 3, Sep 2020. Available from: URL: http:// doi.org/10.15403/jgld-2826
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803517266
Reactions 28 Nov 2020 No. 1832
Data Loading...
